250: Metallo-β-Lactamases: The Rise of NDM and Beyond

OCT 29, 202646 MIN

Description

Metallo-β-lactamases (MBLs) have become an increasingly important topic in clinical microbiology and infectious diseases. While these enzymes were once encountered relatively infrequently in the United States, their epidemiology is changing, with NDM-producing organisms becoming more common. What makes metallo-β-lactamases different from other carbapenemases? Why are infections caused by MBL-producing organisms particularly challenging to treat? And what new treatment options are becoming available? In this episode of Let's Talk Micro, Luis is joined by Dr. Ryan Shields and Dr. Emily Heil to discuss metallo-β-lactamases and their growing clinical significance. They explore the differences between serine β-lactamases and MBLs, review important enzymes such as NDM, VIM, and IMP, and discuss the challenges associated with treating infections caused by MBL-producing organisms. The conversation also covers emerging treatment options, including aztreonam-avibactam and cefepime-zidebactam, and highlights the importance of identifying specific carbapenemases to guide antimicrobial therapy. Join us for a discussion on the evolving landscape of metallo-β-lactamases and the essential role of the clinical microbiology laboratory in patient care. Guests: Ryan Shields, PharmD — University of Pittsburgh Emily Heil, PharmD — University of Maryland School of Pharmacy and University of Maryland Medical Center Additional Reading: McCreary EK, Heil EL, Aitken SL, et al. The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens. JAC-Antimicrobial Resistance. 2026;8(5). https://pubmed.ncbi.nlm.nih.gov/42876900/ Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at [email protected] Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi